The most recent studies include a comparative evaluation of progression-free survival, overall survival, safety, and tolerability in combination with endocrine therapy (ER+/HER2- breast cancer treatment), palbociclib, ribociclib, and abemaciclib [115,116,117,118]. Here, ERBB2 is linked to breast carcinoma.